

Persontilpasset KI-basert nevrodiagnostikk




Esten H. Leonardsen

Post-doktor ved Psykologisk Institutt,
Universitetet i Oslo


Vitenskapelig ansvarlig, baba.vision



UNIVERSITETET
I OSLO




KI-revolusjonen(?)



McKinsey & Company, The state of AI: How organizations are rewiring to capture value,
<https://www.mckinsey.com/capabilities/quantumblack/our-insights/the-state-of-ai> (2025)




KI-revolusjonen(?)



<https://pubmed.ncbi.nlm.nih.gov/>, publikasjoner som inneholder "(neurology OR neuroscience OR neuroimaging) AND (ai OR artificial intelligence OR deep learning)"




KI-revolusjonen(?)



Leonardsen, E. H., ... & Wang, Y. (2024). Constructing personalized characterizations of structural brain aberrations in patients with dementia using explainable artificial intelligence. *NPJ Digital Medicine*, 7(1), 110

KI-revolusjonen(?)




KI-revolusjonen(?)

"Innføringen av KI i helse- og omsorgstjenesten har gått saktere enn noen forventet i starten av planperioden"


Helsedirektoratet (2023). Status og forslag til videre arbeid med kunstig intelligens (KI) i helse- og omsorgstjenesten. Oslo: Helsedirektoratet (siste faglige endring 26. oktober 2023). Tilgjengelig fra <https://www.helsedirektoratet.no/rapporter/status-og-forslag-til-videre-arbeid-med-kunstig-intelligens-ki-i-helse-og-omsorgstjenesten>



Utfordringer: Forklarbarhet




Utfordringer: Forklarbarhet




Utfordringer: Forklarbarhet

Kunstig intelligens




Utfordringer: Forklarbarhet


Kunstig intelligens



Menneskelige forskere



Utfordringer: Nytteverdi



baba.vision



baba.vision





Esten Leonardsen
Chief Scientific Officer



Per Wessel Nore
Chief Executive Officer



Guro Seternes
Chief Technology Officer



Lars T. Westlye
Professor, UiO



Yunpeng Wang
Professor, UiO




Thomas Wolfers
Professor, UT



Anders Eikenes
CEO, Oivi

<https://mlflow-server-531474577141.us-central1.run.app/#/experiments/0>






Prediksjon av behandlingsrespons



**European Medicines Agency reviews
and revises its opinion on Lecanemab**




Prediksjon av behandlingsrespons



Van Dyck, C. H., Swanson, C. J., Aisen, P., Bateman, R. J., Chen, C., Gee, M., ... & Iwatsubo, T. (2023). Lecanemab in early Alzheimer's disease. *New England Journal of Medicine*.




Prediksjon av behandlingsrespons




Villain, N., Planche, V., & Levy, R. (2022). High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects.
Revue neurologique.

Prediksjon av behandlingsrespons




Prediksjon av behandlingsrespons




Prediksjon av behandlingsrespons

Mulighetsstudie



Takk for oppmerksomheten!
estenhl@uios.no



UNIVERSITETET
I OSLO